LON:EVGEvgen Pharma Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Evgen Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 11.60 -0.10 (-0.85 %) (As of 06/5/2020 04:00 PM ET) Add Compare Share Today's Range 11.40Now: GBX 11.60▼ 11.7050-Day Range 8.20MA: GBX 11.34▼ 13.8852-Week Range 2.50Now: GBX 11.60▼ 20.25Volume24,347 shsAverage Volume207,445 shsMarket Capitalization£15.39 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Evgen Pharma. Previous Next 3.0 Community Rank Outperform VotesEvgen Pharma has received 193 “outperform” votes. (Add your “outperform” vote.)Underperform VotesEvgen Pharma has received 133 “underperform” votes. (Add your “underperform” vote.)Community SentimentEvgen Pharma has received 59.20% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Evgen Pharma and other stocks. Vote “Outperform” if you believe EVG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EVG will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldEvgen Pharma does not currently pay a dividend.Dividend GrowthEvgen Pharma does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evgen Pharma insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Evgen Pharma is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evgen Pharma is -5.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvgen Pharma has a P/B Ratio of 2.97. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.60 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:EVG Previous Symbol CUSIPN/A CIKN/A Webevgen.com Phone+44-151-7053532Debt Debt-to-Equity RatioN/A Current Ratio15.56 Quick Ratio15.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowGBX 3.39 per share Price / Cash Flow3.42 Book ValueGBX 3.90 per share Price / Book2.97Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees11 Outstanding Shares132,646,000Market Cap£15.39 million Next Earnings DateN/A OptionableNot Optionable LSE:EVG Rates by TradingView Receive EVG News and Ratings via Email Sign-up to receive the latest news and ratings for EVG and its competitors with MarketBeat's FREE daily newsletter. Evgen Pharma (LON:EVG) Frequently Asked Questions How has Evgen Pharma's stock been impacted by COVID-19 (Coronavirus)? Evgen Pharma's stock was trading at GBX 4.45 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, EVG stock has increased by 160.7% and is now trading at GBX 11.60. View which stocks have been most impacted by Coronavirus. How were Evgen Pharma's earnings last quarter? Evgen Pharma PLC (LON:EVG) released its earnings results on Tuesday, December, 17th. The company reported ($1.43) earnings per share (EPS) for the quarter. View Evgen Pharma's earnings history. Has Evgen Pharma been receiving favorable news coverage? Headlines about EVG stock have trended positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Evgen Pharma earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutEvgen Pharma. Who are some of Evgen Pharma's key competitors? Some companies that are related to Evgen Pharma include InMed Pharmaceuticals (IN), Acerus Pharmaceuticals (ASP), MMJ Group (MMJ), Venture Life Group (VLG), Auscann Group (AC8), Diurnal Group (DNL), Science in Sport (SIS), cbdMD (YCBD), Invion (IVX), Pediapharm (MDP), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals (ZOM), Cipher Pharmaceuticals (CPH), Indiva (NDVA) and Harvest One Cannabis (HVT). View all competitors. What other stocks do shareholders of Evgen Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evgen Pharma investors own include MOTIF BIO PLC/S (MTFB), Capital & Counties Properties PLC (CAPC), Obtala (OBT), Tertiary Minerals (TYM), Veltyco Group (VLTY), Atalaya Mining (AYM), AllianceBernstein Global Hgh Incm Fd (AWF), Advent Claymore Convertible Sec & Inc Fd (AVK), Ares Dynamic Credit Allocation Fund (ARDC) and ETRACS Alerian MLP Index ETN (AMU). Who are Evgen Pharma's key executives? Evgen Pharma's management team includes the following people: Dr. Stephen J. Franklin, CEO & Exec. DirectorMr. Richard Anthony Moulson, CFO & Exec. Director (Age 57)Ms. Liz Jenkins, Regulatory ConsultantDr. Thomas Morris, Consultant & Medical Advisor of OncologyProf. Albena Dinkova-Kostova, Independent Scientific Advisor What is Evgen Pharma's stock symbol? Evgen Pharma trades on the London Stock Exchange (LON) under the ticker symbol "EVG." How do I buy shares of Evgen Pharma? Shares of EVG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Evgen Pharma's stock price today? One share of EVG stock can currently be purchased for approximately GBX 11.60. How big of a company is Evgen Pharma? Evgen Pharma has a market capitalization of £15.39 million. Evgen Pharma employs 11 workers across the globe. What is Evgen Pharma's official website? The official website for Evgen Pharma is evgen.com. How can I contact Evgen Pharma? Evgen Pharma's mailing address is The Colony 146 Brownlow Hill, Altrincham Road, WILMSLOW, SK9 4LY, United Kingdom. The company can be reached via phone at +44-151-7053532. This page was last updated on 6/6/2020 by MarketBeat.com Staff
